LANCET ONCOLOGY

Scope & Guideline

Leading the way in oncology research and clinical excellence.

Introduction

Welcome to your portal for understanding LANCET ONCOLOGY, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1470-2045
PublisherELSEVIER SCIENCE INC
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2000 to 2024
AbbreviationLANCET ONCOL / Lancet Oncol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressSTE 800, 230 PARK AVE, NEW YORK, NY 10169

Aims and Scopes

LANCET ONCOLOGY focuses on disseminating high-quality, peer-reviewed research in the field of oncology, emphasizing the latest advancements in cancer treatment, prevention, and patient care. The journal aims to address significant challenges in cancer research and clinical practice, with a commitment to improving outcomes for cancer patients globally.
  1. Innovative Cancer Therapies:
    The journal publishes studies on novel therapeutic approaches including immunotherapy, targeted therapies, and combination treatments across various cancer types.
  2. Patient-Centered Outcomes:
    Research focusing on health-related quality of life, patient-reported outcomes, and the psychosocial aspects of cancer care is a significant area of interest, emphasizing the importance of patient perspectives in treatment efficacy.
  3. Clinical Trials and Methodological Advances:
    LANCET ONCOLOGY features a wide range of clinical trials, from phase 1 to phase 3, and promotes methodological innovations that enhance trial designs, patient recruitment, and outcome assessments.
  4. Global Cancer Burden and Health Disparities:
    The journal addresses disparities in cancer care and outcomes, particularly in low- and middle-income countries, highlighting global health initiatives and the need for equitable access to cancer treatments.
  5. Translational Research and Precision Medicine:
    Research that bridges laboratory findings with clinical applications, focusing on biomarkers and genomic profiling to tailor cancer treatments to individual patients.
LANCET ONCOLOGY is at the forefront of addressing emerging trends and themes in oncology research, reflecting the dynamic nature of the field. The following areas are gaining prominence in recent publications, demonstrating the journal's responsiveness to evolving challenges and advancements in cancer care.
  1. Immunotherapy and Combination Treatments:
    A significant increase in studies exploring the efficacy of immunotherapies, particularly in combination with other treatment modalities, highlights the growing interest in harnessing the immune system to combat cancer.
  2. Real-World Evidence and Patient Outcomes:
    There is a notable trend towards incorporating real-world evidence in oncology research, focusing on patient outcomes, treatment adherence, and the impact of socio-economic factors on cancer care.
  3. Health Equity and Access to Care:
    Emerging research emphasizes the importance of addressing health disparities, with a focus on improving access to cancer care for underrepresented populations and in low-resource settings.
  4. Precision Medicine and Genomics:
    A rising trend in the application of genomic profiling and precision medicine approaches is evident, with studies exploring how genetic insights can guide tailored cancer therapies.
  5. Environmental and Societal Impacts on Cancer Outcomes:
    Research examining the effects of environmental factors, lifestyle changes, and public health policies on cancer incidence and outcomes is becoming increasingly relevant in the journal.

Declining or Waning

While LANCET ONCOLOGY continues to cover a broad spectrum of oncology research, some themes have seen a decline in prominence. This may reflect shifts in research focus, changing clinical priorities, or advancements in specific areas that have led to saturation.
  1. Traditional Chemotherapy Approaches:
    As newer therapies such as immunotherapy and targeted treatments gain traction, traditional chemotherapy regimens are discussed less frequently, indicating a potential shift in treatment paradigms.
  2. Single-Agent Drug Studies:
    There has been a noticeable decrease in studies focusing solely on single-agent chemotherapy drugs, as combination therapies and multi-drug regimens are increasingly favored for their improved efficacy.
  3. Local Treatment Modalities:
    Research on localized treatment modalities, such as traditional surgery and radiotherapy alone, appears to be waning as the focus shifts towards integrated approaches that combine systemic therapies.
  4. Conventional Diagnostic Techniques:
    The rise of advanced imaging techniques and liquid biopsies has resulted in a decline in the publication of studies centered on conventional diagnostic methods like biopsy and standard imaging.
  5. Basic Science Research in Oncology:
    There is a diminishing focus on basic science research unrelated to clinical applications, as the journal prioritizes translational research that directly impacts patient care.

Similar Journals

BREAST

Shaping the future of oncology with peer-reviewed excellence.
Publisher: CHURCHILL LIVINGSTONEISSN: 0960-9776Frequency: 6 issues/year

BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.

Therapeutic Advances in Medical Oncology

Pioneering open access to vital oncology research.
Publisher: SAGE PUBLICATIONS LTDISSN: 1758-8340Frequency: 1 issue/year

Therapeutic Advances in Medical Oncology, an esteemed journal published by SAGE Publications Ltd, serves as a critical platform for disseminating high-quality research pertinent to the field of oncology. Indexed under the ISSN 1758-8340 and E-ISSN 1758-8359, this Open Access journal has made significant strides since its inception in 2009, attaining a commendable rank of #78 out of 404 in the Medicine - Oncology category of Scopus, placing it in the top 20th percentile of journals. With its category quartile of Q1 established in 2023, it underscores the journal’s commitment to advancing therapeutic approaches in oncology, making it an invaluable resource for researchers, clinicians, and students alike. Offering unrestricted access to pioneering studies since 2017, it aligns with the global movement towards open science, fostering collaboration and innovation among professionals striving to improve cancer treatment outcomes. By bridging the gap between research and clinical practice, Therapeutic Advances in Medical Oncology plays a vital role in shaping the future of cancer therapy.

JTO Clinical and Research Reports

Transforming Research into Practice for Better Patient Outcomes
Publisher: ELSEVIERISSN: Frequency: 12 issues/year

JTO Clinical and Research Reports is an esteemed open-access journal published by Elsevier, dedicated to advancing knowledge in the fields of Oncology and Pulmonary and Respiratory Medicine. Since its inception in 2020, the journal has rapidly gained recognition, achieving a commendable Q1 ranking in both fields as of 2023, highlighting its significant contribution to high-quality research and clinical practice. With an inclusive global reach, JTO Clinical and Research Reports fosters collaboration by allowing unrestricted access to its content, ensuring that vital research findings can be disseminated widely among researchers, clinicians, and students alike. Located in the United States, and with its editorial base in the Netherlands, this journal not only embraces the mission of open science but also strives to publish impactful studies that address critical challenges in cancer treatment and respiratory health. Through its rigorous peer-review process and commitment to excellence, JTO Clinical and Research Reports aims to be at the forefront of scientific discourse and innovation in these dynamic areas of medicine.

ONCOLOGY

Innovating the future of oncology with every publication.
Publisher: KARGERISSN: 0030-2414Frequency: 12 issues/year

ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.

Cancer Research Communications

Innovating cancer treatment through shared insights.
Publisher: AMER ASSOC CANCER RESEARCHISSN: Frequency: 1 issue/year

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

Cancer Management and Research

Illuminating the complexities of oncology for better health.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1322Frequency: 1 issue/year

Cancer Management and Research, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing the field of oncology. Since its inception in 2009, this journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals focused on cancer treatment and management. With its robust impact factor and impressive Scopus ranking in the 77th percentile of oncology medicine, it provides a prominent platform for sharing high-quality research. The journal covers a wide range of topics within cancer management, including innovative therapeutic strategies, clinical trials, patient care, and health policy, ensuring a comprehensive approach to current challenges in the field. Operating from New Zealand, it invites contributions that can shape the future of oncology and improve patient outcomes globally, making it an essential addition to the libraries of those engaged in cancer research and practice.

Future Oncology

Advancing cancer research for a healthier tomorrow.
Publisher: FUTURE MEDICINE LTDISSN: 1479-6694Frequency: 40 issues/year

Future Oncology is a premier peer-reviewed journal published by FUTURE MEDICINE LTD, dedicated to advancing research and innovation within the field of oncology. Established in 2005 and set to continue through 2024, this journal serves as an essential resource for researchers, healthcare professionals, and students engaged in cancer studies. With its emphasis on groundbreaking findings and multidisciplinary approaches, Future Oncology holds an esteemed reputation, reflected in its 2023 category quartiles ranking it in Q2 for Cancer Research and Q1 for Medicine (miscellaneous). The journal is indexed in Scopus, showcasing its rigorous content, with rankings in the 63rd percentile for Oncology and the 46th percentile for Cancer Research. Although it does not operate on an open-access model, its commitment to disseminating cutting-edge findings makes it an invaluable asset for those seeking to stay at the forefront of oncology research.Future Oncology strives to bridge the gap between laboratory and clinical research, fostering collaboration and appreciation for the complexities of cancer treatment.

BRITISH JOURNAL OF CANCER

Pioneering Insights in Oncology Since 1947.
Publisher: SPRINGERNATUREISSN: 0007-0920Frequency: 24 issues/year

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

South Asian Journal of Cancer

Transforming cancer treatment through regional insights.
Publisher: GEORG THIEME VERLAG KGISSN: 2278-330XFrequency: 4 issues/year

South Asian Journal of Cancer, published by GEORG THIEME VERLAG KG, is a pivotal platform for research in the fields of oncology and cancer research. Established in 2012 and operating under an Open Access model, this journal aims to disseminate high-quality, peer-reviewed articles that address crucial developments in cancer treatment, prevention, and research, particularly within the South Asian context. Despite its young history, the journal has been positioned within the Q4 quartile for both Cancer Research and Oncology, and while current Scopus rankings indicate it resides in the lower percentiles, its commitment to amplifying regional voices and research is invaluable. With its headquarters in Stuttgart, Germany, and a global readership, South Asian Journal of Cancer is dedicated to enhancing collaboration among researchers, healthcare professionals, and students, fostering a space for innovative ideas and advancements in cancer care as we progress through to 2024.

INDIAN JOURNAL OF CANCER

Championing Cancer Research in the Heart of India
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0019-509XFrequency: 4 issues/year

INDIAN JOURNAL OF CANCER, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of oncology, providing dedicated insight into cancer research and its clinical applications since its inception in 1965. With an ISSN of 0019-509X and an E-ISSN of 1998-4774, this esteemed journal facilitates the dissemination of knowledge related to cancer prevention, diagnosis, and treatment strategies within the Indian context and beyond. Although classified within the Q3 quartile of oncology journals and ranked #292 out of 404 in its category in the Scopus database, the INDIAN JOURNAL OF CANCER continues to play a vital role in advancing the dialogue around cancer management. This journal is particularly significant for researchers, professionals, and students intent on contributing to the evolving landscape of oncology, offering a platform for sharing innovative findings and fostering collaboration among the academic community. Located in Mumbai, India, the journal's commitment to impactful research is reflected in its ongoing efforts to bridge gaps in cancer knowledge and address the unique challenges faced within the region and globally.